Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naïve patients with HIV-1 infection
| Autor: | Roberto Manfredi, Leonardo Calza, Francesco Chiodo, Daria Pocaterra |
|---|---|
| Přispěvatelé: | L. Calza, R. Manfredi, D. Pocaterra, F. Chiodo |
| Rok vydání: | 2008 |
| Předmět: |
Adult
Diarrhea Male medicine.medical_specialty Anti-HIV Agents Lopinavir/ritonavir HIV Infections Fosamprenavir Pyrimidinones Dermatology Pharmacology Drug Administration Schedule Lopinavir HIV Protease immune system diseases Abacavir Internal medicine Drug Resistance Viral medicine Humans Pharmacology (medical) Treatment Failure Furans Hypertriglyceridemia Sulfonamides Ritonavir business.industry Public Health Environmental and Occupational Health virus diseases Lamivudine Middle Aged Organophosphates Regimen Treatment Outcome Infectious Diseases Tolerability HIV-1 Reverse Transcriptase Inhibitors Drug Therapy Combination Female Carbamates business medicine.drug |
| Zdroj: | International Journal of STD & AIDS. 19:541-544 |
| ISSN: | 1758-1052 0956-4624 |
| DOI: | 10.1258/ijsa.2008.007322 |
| Popis: | Recent data indicate that fosamprenavir/ritonavir as part of an initial antiretroviral regimen in HIV-1 -infected patients is associated with favourable efficacy and tolerability and in the KLEAN study (kaletra versus lexiva with epivir and abacavir in antiretroviral-naive patients) it was found to be non-inferior to lopinavir/ritonavir in association with abacavir/lamivudine. In our open-label, observational study conducted in 82 therapy-naíve HIV-1-infected patients followed-up for 18 months, virological and immunological efficacy was comparable in subjects receiving a fosamprenavir/ritonavir-based and a lopinavir/ritonavir-based treatment (proportions of patients with HIV RNA |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|